Integrating Single-Cell and Spatial Transcriptomics Reveals NK Cell Subpopulations Associated With Immunotherapy for

Zhicheng Hu1, Yongfei Chen1, Hao Yang1

  • 1Department of Burn Surgery The First Affiliated Hospital of Sun Yat-sen University Guangzhou China.

Smart Medicine
|December 8, 2025
PubMed

Insights

Immune checkpoint inhibitors (ICI) show promise in melanoma, but resistance is common. This study identifies specific Natural Killer (NK) cell subtypes crucial for immunotherapy response, offering new therapeutic targets.

Area of Science:

  • Immunology
  • Oncology
  • Genomics

Background:

  • Immune checkpoint inhibitors (ICI) improve melanoma treatment for some patients.
  • Mechanisms of resistance to ICI therapy remain largely unknown.
  • Understanding tumor microenvironment heterogeneity is key to improving immunotherapy.

Purpose of the Study:

  • To investigate the role of Natural Killer (NK) cells in melanoma patient response to immunotherapy.
  • To identify distinct NK cell subpopulations and their functional characteristics.
  • To explore novel therapeutic strategies targeting NK cells for enhanced melanoma treatment.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) to analyze tumor immune cell transcriptomes.
  • Identification and characterization of NK cell subpopulations.
  • Spatial transcriptomics (ST) to map NK cell interactions within the tumor microenvironment.
  • Molecular docking to assess the feasibility of targeting specific NK cell subsets.

Main Results:

  • NK cells are significantly linked to patient response to immunotherapy.
  • Four distinct NK cell subpopulations were identified, each with unique marker genes and functions.
  • NK cluster 01 was found to be critical for patient sensitivity and prognosis.
  • NK cluster 01 cells are spatially located near melanoma cells, suggesting interaction via the IFN-II pathway.
  • Molecular docking indicates potential for small molecule drugs to target NK cluster 01 cells.

Conclusions:

  • NK cell heterogeneity plays a crucial role in melanoma immunotherapy outcomes.
  • NK cluster 01 represents a promising therapeutic target for improving ICI efficacy.
  • Targeting specific NK cell subsets could enhance the clinical utility of NK cell-based therapies for melanoma.